CONFIDENTIAL TREATMENT EXHIBIT 10.21
WEB SOFTWARE LICENSING AND DEVELOPMENT AGREEMENT
This Web Software Licensing and Development Agreement is entered into as of
September 10, 1999 (the "Effective Date") between AWARE, Inc. ("AWARE") and eMed
Technologies Corporation ("EMED"), formerly known as ACCESS Radiology
Corporation.
Background
----------
1. EMED is in the business of providing integrated hardware and software
systems and services with respect to the transmission and interpretation of
medical images. AWARE develops and licenses proprietary computer software that
is useful for compression and web-based viewing of digital images.
2. AWARE and EMED are parties to a Software Licensing and Development
Agreement dated May 30, 1997 (the "1997 Agreement"). The 1997 Agreement provides
for the licensing of various software by AWARE to EMED on the terms set forth
therein. Among other things, the 1997 Agreement contemplated the development,
licensing and marketing of certain new software, referred to in the 1997
Agreement as the "Joint Product". The 1997 Agreement sets forth procedures under
which the Joint Product would be developed and licensed, royalties would be
negotiated, and ownership of intellectual property would be determined.
3. The development efforts contemplated with respect to the Joint Product
by the 1997 Agreement have now resulted in the initial commercial release of a
software application for the web-based viewing and distribution of medical
images and related information. This release having occurred, AWARE and EMED now
wish to provide for definitive terms upon which this new software will be
licensed and marketed, and upon which further development work relating to the
new software will proceed.
NOW, THEREFORE, the parties agrees as follows:
Confidential Treatment
1
I. MODIFICATION OF THE 1997 AGREEMENT.
1.01. Termination of Joint Product Provisions. Article III of the 1997
----------------------------------------
Agreement, which provides for various matters relating to the "Joint Product" as
defined therein, shall terminate upon the execution of this Agreement. In
addition, references to the Joint Product in Articles IV, V and VI of the 1997
Agreement shall have no further force or effect upon the execution of this
Agreement. The rights and obligations of AWARE and EMED with respect to the Web
Product and the related Licensed Software (as defined in Section 2.01 of this
Agreement), and with respect to the Joint Product (as defined Article III of
this Agreement)shall be governed exclusively by this Agreement, and not by the
1997 Agreement. The rights and obligations of AWARE and EMED with respect to the
"Compression Software" (as defined in the 1997 Agreement) shall be governed
exclusively by the 1997 Agreement, and not by this Agreement.
1.02 Survival of the 1997 Agreement. The 1997 Agreement shall survive the
-------------------------------
execution of this Agreement and shall continue to govern the rights and
obligations of the parties with respect to the "Compression Software" (as
defined in the 1997 Agreement), except to the extent expressly modified by this
Agreement. The references to "Schedule I" in Sections 1.01, 1.03(b), 1.04(a),
and 2.02(b) of the 1997 Agreement are amended to refer to "the documentation
separately supplied by AWARE".
II. LICENSING OF SOFTWARE; PAYMENTS.
2.01 Grant of License. Subject to the terms of this Agreement, AWARE
-----------------
grants to EMED the following rights, under any patent, copyright, trade secret
or other proprietary right (other than any trademark) of AWARE, whether
presently held or hereafter acquired, with respect to (i) the proprietary web-
based image viewing and distribution software identified on Schedule I and any
upgrades or modifications thereof (the "Web Product") and (ii) any other web-
based image viewing or distribution software developed by AWARE pursuant to this
Agreement (such software and the Web Product being referred to collectively as
the "Licensed Software"):
Confidential Treatment
2
(a) The right to use the Licensed Software for internal purposes and
in support of users of EMED products for Medical Use, and to use and make
available the Licensed Software as part of EMED's product line and for
integration with other components of EMED products.
(b) The right to grant sublicenses of the Licensed Software for
Medical Use to users of EMED products and to original equipment
manufacturers or other parties which utilize toolkits to create derivative
products for Medical Use which are in turn licensed to end users.
Sublicenses of software will be granted in compliance with the procedures
set forth in Section 6.01.
(c) The right to modify the Licensed Software to create new releases
and new products for Medical Use, and to grant sublicenses of software as
modified for Medical Use to users and to original equipment manufacturers
or other parties which utilize toolkits to create derivative products for
Medical Use which will in turn be licensed to end users. Sublicenses of
software will be granted in compliance with the procedures set forth in
Section 6.01.
For purposes of the Agreement, "Medical Use" means the compression,
transmission, viewing or other processing of medical images. The rights granted
to EMED shall be exclusive to the extent set forth in Article III.
2.02. License Fees. (a) License fees payable to AWARE with respect to the
-------------
Web Product will be determined based upon the terms on which the Web Product is
made available to customers. [*Redacted pursuant to a Confidential Treatment
Request dated September 10, 1999.
Confidential Treatment
3
]
(b) With respect to each Subscription Sale of the Web Product, EMED will
pay to AWARE [*Redacted pursuant to a Confidential Treatment Request dated
September 10, 1999.
]
(c) With respect to sales of the Web Product other than Subscription
Sales, [*Redacted pursuant to a Confidential Treatment Request dated September
10, 1999.]
(d) [*Redacted pursuant to a Confidential Treatment Request dated
September 10, 1999.
]
(e) [*Redacted pursuant to a Confidential Treatment Request dated
September 10, 1999.
]
(f) [*Redacted pursuant to a Confidential Treatment Request dated
September 10, 1999.
] EMED
will not make the Web Product available without charge
Confidential Treatment
4
except for (i) [*Redacted pursuant to a Confidential Treatment Request dated
September 10, 1999 ] and (ii) copies of client software provided to
radiologists in connection with Subscription Sales, and EMED will not make the
Web Product available without charge to assist in selling other products or in
generating revenues from other sources.
2.03. Payments. (a) Promptly after the end of each calendar quarter, EMED
---------
will deliver to AWARE a statement setting forth, for such quarter, the number of
copies of server software included in Subscription Sales, Net Client License
Revenue, and Net Software License Revenue. Each quarterly statement shall be
accompanied by payment of license fees due. EMED will use its best efforts to
provide such statement and pay license fees due within 30 days of the end of
each calendar quarter. Each quarterly statement and payment of license fees
shall be provided no later than 60 days after the end of the relevant calendar
quarter.
(b) EMED will keep complete books of account containing all particulars
that may be necessary to determine the amounts payable to AWARE hereunder. Such
books and supporting data shall be open for inspection for one year following
the calendar year to which they pertain, at reasonable times and upon reasonable
notice, by an independent auditor for purposes of verifying the statements
delivered pursuant to subsection (a) above. AWARE will not conduct more than one
such inspection for books and supporting data relating to any single calendar
year. The results of any inspection shall be made available to EMED. If the
agreed results of an inspection show an underpayment or overpayment, then EMED
shall pay to AWARE the amount of any underpayment and AWARE shall pay to EMED
the amount of any overpayment. [*Redacted pursuant to a Confidential Treatment
Request dated September 10, 1999.
]
2.04. Other Products. With respect to Licensed Software that may be
---------------
developed in the future, the parties will negotiate in good faith to determine
definitive terms.
Confidential Treatment
5
[*Redacted pursuant to a Confidential Treatment Request dated September 10,
1999.
]
III. MARKETING FOR NON-MEDICAL USE.
3.01 AWARE shall have the exclusive right to market software and other
components included in the Web Product and any other software developed pursuant
to this Agreement (the "Joint Product"), under any patent, copyright, trade
secret or other proprietary right of EMED (other than any trademark), whether
presently held or hereafter acquired, for all uses other than Medical Use. AWARE
shall have the following rights with respect to the Joint Product, which EMED
hereby grants to AWARE.
(a) The right to use the Joint Product for internal purposes and in
support of users of AWARE products, and to use and make available the Joint
Product as part of AWARE's product line and for integration with other
components of AWARE products, in all cases for uses other than Medical Use.
Medical Use includes grants of licenses to indemnity insurance companies,
and AWARE will not grant any such licenses.
(b) The right to make and have made, use and have used, and sell,
lease or otherwise transfer the Joint Product, and to grant sublicenses of
the software and other intellectual property included in the Joint Product
to users of AWARE products in which such software is included, in all cases
for uses other than Medical Use. Users to whom sublicenses are granted may
include original equipment manufacturers or other parties which utilize
toolkits to create derivative products for any use other than for Medical
Use, which will in turn be licensed to end users. Sublicenses of software
will be granted in compliance with the procedures set forth in Section
7.01.
(c) The right to modify the Joint Product and the software included
in it to create new releases and new products, to make and have made, use
and have used, and sell, lease or otherwise transfer products including
modifications, and to grant sublicenses of
Confidential Treatment
6
software as modified to users of AWARE products in which such software is
included, in all cases for uses other than Medical Use. Users to whom
sublicenses are granted may include original equipment manufacturers or
other parties which utilize toolkits to create derivative products for any
use other than for Medical Use, which will in turn be licensed to end
users. Sublicenses of software will be granted in compliance with the
procedures set forth in Section 7.01.
[*Redacted pursuant to a Confidential Treatment Request dated September 10,
1999.
]
IV. EXCLUSIVITY
4.01 Exclusivity Commitments. (a) EMED shall have the exclusive right to
------------------------
use and sublicense software developed or owned by AWARE for Medical Use to the
extent set forth herein. From the date of this Agreement until the
Confidential Treatment
7
termination of exclusivity as provided in Section 6.01, AWARE will not (except
as expressly permitted by this Agreement) supply for Medical Use or permit any
person to use for Medical Use (i) the Web Software or any modification or
improvement of the Web Software or (ii) any other dynamic HTML or plug-in
product that is developed, owned or licensed by AWARE. AWARE will take
reasonable steps to assure compliance with this exclusivity commitment by third
parties to whom AWARE provides software. Notwithstanding anything contained in
this Agreement, AWARE may provide its ADSL, SDSL, HFC and any other general data
communication product to third parties for Medical Use or any other purpose.
(b) From the date of this Agreement until the termination of exclusivity
as provided in Section 6.01, AWARE will be the exclusive supplier to EMED of
web-based image viewing and distribution software for use in EMED products. EMED
will not independently develop any such software and will not include any such
software (other than that developed by or in cooperation with AWARE under this
Agreement) in the Web Product or any product that is competitive with the Web
Product. The parties understand and agree that home, diagnostic and intensive
care unit viewers are complementary to the Web Product and are therefore not
within the scope of the foregoing restrictions.
4.02. Exceptions. (a) Licenses of software for Medical Use which have been
-----------
previously granted and for which all license fees have been invoiced as of the
date of this Agreement shall continue in effect notwithstanding Section 4.01.
However, AWARE will not provide upgrades or new releases for any software
subject to such licenses except as expressly permitted in this Section 4.02.
(b) [*Redacted pursuant to a Confidential Treatment Request dated
September 10, 1999.
]
(c) [*Redacted pursuant to a Confidential Treatment Request dated
September 10, 1999.
Confidential Treatment
8
]
4.03. Transition. Promptly after the date of this Agreement, AWARE will
-----------
publicly announce that it has enlarged its exclusive relationship with EMED and
that EMED and AWARE are making a commitment to the Web Product. This
announcement will be subject to review by EMED before its release. EMED may
disclose the relationship between AWARE and EMED contemplated by this Agreement
in technical and product oriented marketing materials without review by AWARE.
EMED may disclose this Agreement and the relationship contemplated hereby in
filings with securities regulators to the extent set forth in Section 7.06. All
other public announcements by EMED that refer to AWARE will be subject to review
by AWARE prior to their release.
V. DUTIES OF EMED AND AWARE
5.01. Duties of EMED. EMED will use its best efforts to maximize the market
---------------
and sales volume for the Web Product. [*Redacted pursuant to a Confidential
Treatment Request dated September 10, 1999.
]
5.02. Duties of AWARE. AWARE will continue to provide primary engineering
----------------
application development for EMED's web-based image viewing and distribution
software for use in EMED products including the client software and dynamic HTML
generation applications included in the Web Product. AWARE's responsibilities
will specifically include bug fixes, work-arounds and other software support as
needed to cause the Licensed Software to perform in accordance with its
specifications. AWARE will also make available, upon request by EMED, additional
applications, additional features on existing applications, and changes to core
technology as specified by EMED. [*Redacted pursuant to a Confidential Treatment
Request dated September 10, 1999.
Confidential Treatment
9
]
5.03. Meetings. Management of AWARE and EMED will meet on a monthly basis
---------
to review technical and market progress towards meeting goals and objectives.
VI. TERM
6.01. Term; Effect of Expiration. (a) The initial term of this Agreement
---------------------------
shall extend until December 31, 2005. The term of this Agreement may be renewed
by mutual agreement of the parties.
(b) [*Redacted pursuant to a Confidential Treatment Request dated
September 10, 1999.
]
(c) AWARE and EMED agree that the royalties and license fees payable under
this Agreement shall be modified effective upon modification of the licenses
granted hereunder pursuant to subsection (b) above. AWARE and EMED further agree
that the appropriate amount of such modified royalties and license fees cannot
be determined as of the date of this Agreement. [*Redacted pursuant to a
Confidential Treatment Request dated September 10, 1999.
] If, at any time after the end of such three month period, either
party shall determine in its judgment that negotiations are unlikely to result
in an acceptable outcome, such party may initiate arbitration to determine
modified fees and royalties pursuant to the procedures specified in Section
8.01.
6.02. Termination for Breach. (a) If EMED shall materially breach its
-----------------------
obligations under this Agreement, and such material breach shall be continuing
for at least 60 days after delivery of a notice by AWARE describing such breach,
then AWARE may by a separate notice terminate this Agreement for breach under
this Section 6.02(a).
Confidential Treatment
10
(b) If AWARE shall materially breach its obligations under this Agreement,
and such material breach shall be continuing for at least 60 days after delivery
of a notice by EMED describing such breach, then EMED may by a separate notice
terminate this Agreement for breach under this Section 6.02(b).
(c) With respect to the obligations of AWARE and EMED under Sections 5.01
and 5.02, "material breach" means willful failure of a party to allocate the
resources required by the Section 5.01 or 5.02 (as the case may be) to the
performance of such party's responsibilities.
(d) Termination for breach under this Section 6.02 shall not be an
exclusive remedy, but shall be in addition to any other remedies that either
party may have.
6.03. Effect of Termination for Breach. (a) If AWARE shall terminate this
---------------------------------
Agreement for breach pursuant to Section 6.02, then the license granted to EMED
pursuant to Section 2.01 shall immediately terminate and EMED shall cease using
or marketing the Licensed Software and the Web Product; provided that EMED shall
fulfill any maintenance obligations existing as of the effective date of such
termination. Upon the effectiveness of such a termination, the exclusivity
obligations of AWARE pursuant to Article III shall terminate.
(b) If EMED shall terminate this Agreement for breach pursuant to Section
6.02, then the license granted to EMED pursuant to Section 2.01 and the
exclusivity provisions binding upon AWARE pursuant to Article IV shall remain in
effect, and the exclusivity obligations of EMED pursuant to Article IV shall
terminate. In such event, AWARE shall continue to provide bug fixes, work-
arounds and other software support as needed to cause the Licensed Software to
perform in accordance with its specifications. Also in such event, EMED shall
retain source code delivered under Section 7.03, AWARE shall deliver to EMED any
additional source code of the Licensed Software not previously delivered under
Section 7.03, and EMED shall continue to have the right to modify the Licensed
Software. For so long as the license granted under Section 2.01 continues in
effect pursuant to this subsection (b), EMED shall pay license fees as provided
in Section 2.02. Upon the effectiveness of any termination by EMED for breach
under
Confidential Treatment
11
Section 6.02(b), the license granted to AWARE under Article III shall
terminate.
6.04. Additional Surviving Terms. All payment obligations accrued prior to
---------------------------
any termination or expiration of this Agreement shall survive such termination
or expiration. All sublicenses granted to any end user in accordance with this
Agreement prior to any termination or expiration of this Agreement shall survive
such termination or expiration. If EMED holds a continuing license under this
Agreement, EMED shall also continue to have the rights set forth in Section 7.03
with respect to such license. The provisions of Sections 6.05, 7.02, 7.05, 7.06,
8.01, 8.02, 8.03 and 8.12 shall survive any termination or expiration of this
Agreement.
6.05. Intellectual Property. AWARE and EMED shall negotiate in good faith
----------------------
for at least three months after effectiveness of expiration or termination of
this Agreement to reach agreement on specific definition of the intellectual
property owned by each party in accordance with the principles set forth in
Section 7.02. If, at any time after the end of such three month period, either
party shall determine in its judgment that negotiations are unlikely to result
in an acceptable outcome, such party may initiate arbitration to determine
ownership of intellectual property pursuant to the procedures specified in
Section 8.01.
VII. INTELLECTUAL PROPERTY
7.01. Software Licensing Procedures. (a) The procedures set forth in this
------------------------------
Section 67.01 shall govern the granting of sublicenses of software under this
Agreement.
(b) Each of AWARE and EMED shall assign a unique number to each copy made
by it of Licensed Software or any other software provided to it by the other
party, whether for internal use or for sublicense to a user. Each of AWARE and
EMED shall keep full, clear and accurate records of all copies that it makes of
any such software and the identity and location of each third party to whom any
such software is provided. Each of EMED and AWARE may examine records of the
other party not more than once in any calendar quarter, during normal business
hours and upon reasonable notice.
Confidential Treatment
12
(c) Sublicenses of software granted under this Agreement shall include the
following provisions. Such terms may be set forth in a reasonably prominent
printed or electronic document that accompanies the software being sublicensed
and states that by use of such software, the user agrees to the terms set forth
in the document. Sublicenses may be granted directly, or by a reseller or other
intermediary. The provisions required by this subsection (c) are:
(i) a provision restricting the sublicensee's use of the licensed
software to its own business and professional purposes, provided that any
sublicensee of a toolkit may use it to create new applications to be
licensed to end users as part of the sublicensee's product;
(ii) a provision requiring the sublicensee to take all reasonable
precautions to keep the licensed software and any related documentation
confidential;
(iii) a provision prohibiting the sublicensee from reproducing
(except for backup copies), reverse engineering, translating or creating
other versions of the licensed software, provided that any sublicensee of a
toolkit may use it to create new applications to be licensed to end users
as part of the sublicensee's product;
(iv) a provision acknowledging that ownership of the licensed
software remains exclusively with the grantor of the license or its
suppliers;
(v) a provision limiting the other party's liability to the
sublicensee to at least the same extent that the liability of the grantor
to the sublicensee is limited, and disclaiming warranties on behalf of the
other party at least to the extent disclaimed on behalf of the grantor; and
Confidential Treatment
13
(vi) a provision stating that AWARE or EMED (as the case may be) is
an intended third party beneficiary of the foregoing to the extent any
materials or information delivered to the sublicensee originated with or
are derived from materials or information supplied by AWARE or EMED (as the
case may be), and shall have the right to enforce and shall be entitled to
the benefit of any of the foregoing provisions as they relate to such
materials or information.
Each party will use reasonable efforts to enforce license agreements executed by
its customers. In no event shall source code be released to any sublicensee.
(d) Notwithstanding this Section 7.01 or any other provision of this
Agreement, software may be licensed to the Government of the United States of
America, or an agency or instrumentality thereof, under an agreement containing
software licensing terms generally used by the United States Government (or the
agency or instrumentality to which the software is licensed) for procurement of
commercial software.
7.02. Ownership. (a) As between EMED and AWARE, AWARE owns any software
----------
developed solely by AWARE or by any employee, consultant or other person acting
on AWARE's behalf (other than EMED) under this Agreement, including any
inventions, concepts, specifications, know-how and ideas embodied in such
software, together with all proprietary rights therein ("AWARE Intellectual
Property"). As between EMED and AWARE, EMED owns and shall continue to own those
concepts, specifications, know-how, and ideas embodied in the design and
functionality of the Web Product and conceived solely by EMED, and as applied in
the Web Product for Medical Use, and any software developed solely by EMED or by
any employee, consultant or other person acting on EMED's behalf (other than
AWARE) under this Agreement, including any inventions, concepts, specifications,
know-how and ideas embodied in any of the foregoing, together with all
proprietary rights therein ("EMED Intellectual Property"). As between EMED and
AWARE, the parties shall jointly own any software or other intellectual property
jointly developed by the parties under this Agreement and not allocated between
them above, including any inventions, concepts, specifications, know-how and
ideas embodied therein, together with all
Confidential Treatment
14
proprietary rights therein ("Joint Intellectual Property"). Whether or not any
intellectual property is jointly developed shall be determined in accordance
with United States patent or copyright law as applicable; provided that in no
event shall either party have an obligation to account to the other except as
specifically provided in this Agreement.
(b) AWARE shall have the right to file and prosecute patent or copyright
applications on AWARE Intellectual Property and EMED shall have the right to
file and prosecute patent or copyright applications on EMED Intellectual
Property. The parties will cooperate in the filing and prosecution of patent or
copyright applications on Joint Intellectual Property, provided that neither
party shall file any such patent or copyright application without the prior
written consent of the other. Each party will cooperate with the other party in
the filing and prosecution by the other party of any patent or copyright
application that complies with this subsection (b), including by executing and
delivering or causing its officers and employees to execute and deliver (all at
the expense of the filing party) any documentation reasonably necessary or
appropriate for the filing and prosecution of such an application and the
vesting of rights as provided in this Agreement.
(c) The exclusivity obligations of the parties under Article IV shall not
in any way be affected by the ownership of AWARE Intellectual Property, EMED
Intellectual Property, or Joint Intellectual Property as provided in this
Section 7.02, or by the filing of any patent or copyright application or the
grant or issuance of any patent or copyright. Neither party shall market, sell,
license or distribute any Joint Intellectual Property except to the extent that
such Joint Intellectual Property is covered by a license granted to such party
hereunder.
7.03 Source Code. Copies of source code of all Licensed Software will be
------------
made available to EMED by AWARE upon completion of each release or patch in
which such source code is included. The fact that AWARE has provided access to
source code shall in no way affect proprietary rights to source code or
software, and all source code shall continue to be owned by the party that owned
it prior to disclosure. All source code is "Confidential Information" as that
term is used in Section 7.06 and shall
Confidential Treatment
15
be subject to the restrictions set forth in Section 7.06. EMED will maintain
source code revision control procedures with which both AWARE and EMED will
comply. These procedures will be designed to achieve, among other things,
compliance with "Good Manufacturing Practices" as defined by the U.S. Food and
Drug Administration and documentation of the ownership of source code disclosed
by either party. Provision of source code to EMED shall not affect AWARE's
obligations to provide engineering resources and support under Section 5.01.
Should AWARE wish to utilize its license rights pursuant to Section 3.01, AWARE
will notify EMED of such intentions and copies of source code of Joint Products
will be made available to AWARE by EMED upon completion of each release or patch
in which such source code is included. The fact that EMED has provided access to
source code shall in no way affect proprietary rights to source code or
software, and all source code shall continue to be owned by the party that owned
it prior to disclosure. All source code is "Confidential Information" as that
term is used in Section 7.06 and shall be subject to the restrictions set forth
in Section 7.06.
7.04. Representations. (a) AWARE represents to EMED that AWARE has full
----------------
authority to enter into this Agreement and grant the licenses and rights set
forth herein.
(b) EMED represents to AWARE that EMED has full authority to enter into
this Agreement and grant the licenses and rights set forth herein.
7.05. Indemnities. (a) AWARE will, at its expense, defend against, hold
------------
EMED harmless from, and pay any final judgment against EMED or any customer of
EMED arising out of (x) any claim that the Licensed Software infringed a
copyright, a patent or a trade secret of a third party, unless in the case of
third party patent claims, (i) AWARE can show that the patent claimed to have
been infringed was not known to Aware at the time of delivery to EMED of the
infringing portion of Licensed Software or (ii) such patent was infringed in
order to comply with an EMED design or specification or (iii)such patent would
not be infringed by the use of Licensed Software alone and not in combination
with any EMED software; or (y) out of marketing by AWARE of AWARE products
(including any product liability claim unless such product liability claim is
caused by designs, specifications or software provided by EMED); provided that
(i) EMED notifies AWARE in writing of such claim or action,
Confidential Treatment
16
and (ii) AWARE has sole control of the defense and settlement of such claim or
action. In defending against such claim or action to the extent it relates to
software provided by AWARE, AWARE may, at its option, agree to any settlement in
which AWARE shall either (1) procure for EMED and all customers of EMED the
right to continue using the software at issue; or (2) modify or replace such
software so that it no longer infringes, to the extent that the exercise of such
option does not result in a material adverse change in the operational
characteristics of such software, and equivalent functions and performance
provided by AWARE remain following implementation of such option. If AWARE
concludes in its judgment that none of the foregoing options is reasonable,
AWARE may remove the software at issue and any other component supplied by AWARE
rendered unusable as a result of such removal and pay to EMED damages arising
therefrom, including damages incurred by reason of EMED's inability to perform
its obligations under sublicenses; [*Redacted pursuant to a Confidential
Treatment Request dated September 10, 1999.]
(b) EMED will, at its expense, defend against, hold AWARE harmless from,
and pay any final judgment against AWARE or any customer of AWARE arising out of
(x) any claim that any software licensed to AWARE by EMED hereunder infringed a
copyright, a patent or a trade secret of a third party, unless in the case of
third party patent claims, (i) EMED can show that the patent claimed to have
been infringed was not known to EMED at the time of delivery to AWARE of the
infringing software or (ii) such patent was infringed in order to comply with an
AWARE design or specification or (iii) such patent would not be infringed by the
use of the software licensed by EMED alone and not in combination with any AWARE
software; or (y) out of marketing by EMED of EMED products (including any
product liability claim unless such product liability claim is caused by
designs, specifications or software provided by AWARE) provided that (i) AWARE
notifies EMED in writing of such claim or action, and (ii) EMED has sole control
of the defense and settlement of such claim or action. In defending against such
claim or action to the extent it relates to software provided by EMED, EMED may,
at its option, agree to any settlement in which EMED shall either (1) procure
for AWARE and all customers of AWARE the right to continue using the software at
issue; or (2) modify or
Confidential Treatment
17
replace such software so that it no longer infringes, to the extent that the
exercise of such option does not result in a material adverse change in the
operational characteristics of such software, and equivalent functions and
performance provided by EMED remain following implementation of such option. If
EMED concludes in its judgment that none of the foregoing options is reasonable,
EMED may remove the software at issue and any other component supplied by EMED
rendered unusable as a result of such removal and pay to AWARE damages arising
therefrom, including damages incurred by reason of AWARE's inability to perform
its obligations under sublicenses; [*Redacted pursuant to a Confidential
Treatment Request dated September 10, 1999.]
(c) If EMED shall determine in its judgment that the concepts,
specifications, know-how, and ideas embodied in the design and functionality of
the Licensed Software infringe or conflict with a patent or copyright not known
to EMED on the date of this Agreement, then EMED shall notify AWARE and the
parties will discuss in good faith whether the Licensed Software can be modified
or other steps may be taken to avoid such infringement. If EMED determines in
its judgment that no such modification or other steps can be reasonably
implemented, EMED may by notice terminate the obligations of AWARE and EMED
under this Agreement with respect to the affected portion of the Licensed
Software, and the indemnity of EMED in subsection (b) above shall apply only to
those claims relating to the affected portion of the Licensed Software of which
AWARE or EMED had notice prior to the date of the first notice regarding
infringement delivered by EMED.
7.06. Confidentiality. As used in this Agreement, "Confidential
----------------
Information" means (i) all confidential information, proprietary software, trade
secrets, know-how, and all other intellectual property that is subject to the
licenses granted in this Agreement and in which proprietary rights would be
adversely affected by disclosure and (ii) all other confidential or proprietary
information (including without limitation financial information and business
information such as customer lists) that is or has been disclosed by AWARE to
EMED or by EMED to AWARE. AWARE and EMED agree that they will not, and will not
permit
Confidential Treatment
18
their respective officers, employees, agents and representatives to, without
first obtaining the written consent of the other party, use, sell or disclose
any Confidential Information, except as expressly contemplated hereby and except
that Confidential Information may be disclosed by the party that owns it unless
such disclosure would adversely affect the proprietary nature of Confidential
Information subject to any of the licenses granted hereunder. Either party may
disclose Confidential Information to potential customers, and to other third
parties to the extent necessary to permit any such third party to assist in
manufacture or integration of the Web Product, provided that any such potential
customer or third party to whom Confidential Information is disclosed shall
execute a confidentiality agreement no less restrictive than this Section 7.06.
"Confidential Information" does not include (i) information that is or becomes
(other than by disclosure in violation of this Agreement) generally available to
the public, (ii) information that the receiving party can show was known to the
receiving party prior to its disclosure by the other party, or (iii) information
required to be disclosed by law or regulation or by judicial process or
administrative order, provided that prompt notice and an opportunity to seek a
protective order is given to the other party prior to disclosure. AWARE and EMED
agree that this Agreement and the Schedules hereto are Confidential Information
subject to this Section 7.06. AWARE consents to the disclosure of the
relationship contemplated by this Agreement in filings by EMED with the U.S.
Securities and Exchange Commission and state securities authorities, and the
filing of this Agreement and the 1997 Agreement as related exhibits; provided
that EMED shall diligently seek confidential treatment of all pricing
information and shall promptly deliver a copy of all such filings to AWARE.
VIII. GENERAL.
8.01. Arbitration. Any controversy or claim arising out of or relating to
------------
this Agreement, or the breach thereof, shall be settled by arbitration
administered by the American Arbitration Association in Boston, Massachusetts
under its Commercial Arbitration Rules, and judgment on the award rendered by
the arbitrator(s) may be entered in any court having jurisdiction thereof.
Arbitration as specified in this Section 8.01 shall be the sole and exclusive
procedure for the resolution of disputes
Confidential Treatment
19
between the parties arising out of or relating to this Agreement or the breach
thereof; provided, however, that a party, without prejudice to such procedure,
may file a complaint to seek a preliminary injunction or other provisional
judicial relief, if in its judgment such action is necessary to avoid
irreparable damage or preserve the status quo. Despite such action the parties
will continue to participate in good faith in the procedures specified in this
Section 8.01. AWARE and EMED agree that any breach of Sections 4.01, 4.02, 7.01
or 7.06 would cause irreparable harm and that the aggrieved party shall be
entitled to equitable relief in the nature of an injunction for any such breach,
without posting of a bond or other surety.
8.02. Limitation of Warranties. THE OBLIGATIONS OF AWARE AND EMED EXPRESSLY
-------------------------
STATED IN THIS AGREEMENT ARE IN LIEU OF ALL OTHER WARRANTIES OR CONDITIONS
EXPRESS OR IMPLIED. TO THE EXTENT ALLOWABLE TO BY LAW, THIS EXCLUSION OF ALL
OTHER WARRANTIES AND CONDITIONS EXTENDS TO IMPLIED WARRANTIES OR CONDITIONS OF
MERCHANTABLE QUALITY AND FITNESS FOR A PARTICULAR PURPOSE, OR AGAINST
INFRINGEMENT AND THOSE ARISING BY STATUTE OR OTHERWISE IN LAW, OR FROM A COURSE
OF DEALING OR USAGE OF TRADE.
8.03. Limitation of Liability. EMED AND AWARE AGREE THAT, EXCEPT AS
------------------------
EXPRESSLY STATED OTHERWISE IN SECTION 7.05, THE LIABILITY OF EITHER OF THEM TO
THE OTHER, IF ANY, UNDER ANY THEORY OF LAW OR EQUITY, ARISING OUT OF, OR IN ANY
WAY RELATED TO THIS AGREEMENT OR THE FULFILLMENT OF ANY OF THE OBLIGATIONS OF
EITHER OF THEM UNDER THIS AGREEMENT, IS LIMITED TO MONEY DAMAGES NOT TO EXCEED
THE TOTAL AMOUNT PAID OR PAYABLE BY EMED TO AWARE UNDER THIS AGREEMENT.
8.04. Governing Law. This Agreement shall be governed by and construed in
--------------
accordance with the laws of the Commonwealth of Massachusetts.
8.05. Assignment. (a) Subject to EMED's right to grant sublicenses
-----------
hereunder, EMED may not assign this Agreement or any rights hereunder without
the prior written consent of AWARE, except that, without such consent and upon
notice to AWARE, (i) EMED may assign all of its rights hereunder to a
corporation or other legal entity that acquires substantially all of EMED's
assets or where EMED is consolidated or merged, but then only upon the express
assumption by such transferee or its successor of the
Confidential Treatment
20
obligations set forth in this Agreement and (ii) EMED may grant security
interests in the rights of EMED under this Agreement to secure the obligations
of EMED to a bank or other financial institution which has extended credit to
EMED.
(b) AWARE may not assign this Agreement or any rights hereunder without
the prior written consent of EMED, except that, without such consent and upon
notice to EMED, (i) AWARE may assign all of its rights hereunder to a
corporation or other legal entity that acquires substantially all of AWARE's
assets or where AWARE is consolidated or merged, but then only upon the express
assumption by such transferee or its successor of the obligations set forth in
this Agreement and (ii) AWARE may grant security interests in the rights of
AWARE under this Agreement to secure the obligations of AWARE to a bank or other
financial institution which has extended credit to AWARE.
(c) This Agreement is binding upon, and inures to the benefit of, the
successors and permitted assigns of the parties.
8.06. Effect of Waiver. The waiver or failure of either party to exercise
-----------------
in any respect any right provided for in this Agreement shall not be deemed a
waiver of any further or future right hereunder.
8.07. Headings. The headings used in this Agreement are for convenience of
---------
reference only and are not to be used in interpreting the provisions of this
Agreement.
8.08. Complete Agreement. This Agreement is the exclusive statement of the
-------------------
understanding between the parties with respect to its subject matter. It
supersedes all prior agreements, negotiations, representations and proposals,
written or oral, relating to the subject matter hereof. No provisions of this
Agreement may be changed or modified except by an agreement in writing signed by
the party to be bound. No provision of any purchase order or other instrument
issued by EMED or any invoice or other form issued by AWARE that is inconsistent
with the provisions of this Agreement shall be binding or affect this Agreement
unless signed by both parties.
Confidential Treatment
21
8.09. Severability. If any provision of this Agreement is invalid or
-------------
unenforceable in any particular case, such case shall not invalidate or render
unenforceable any other part of this Agreement. This Agreement shall be
construed as not containing the particular provision or provisions held to be
invalid or unenforceable to the extent of the particular case, and the rights
and obligations of the parties hereto shall be construed and enforced
accordingly.
8.10. Effectiveness of Agreement; Counterparts. This Agreement is effective
-----------------------------------------
when executed by both parties. This Agreement may be executed in counterparts,
each of which shall constitute one and the same instrument.
8.11. Notices. All notices provided for in this Agreement shall be in
--------
writing or facsimile, addressed to the appropriate party at the respective
address set forth below or to such other then-current address as is specified by
notice, as follows:
to AWARE:
AWARE, Inc.
▇▇ ▇▇▇▇▇▇▇▇▇ ▇▇▇▇▇▇▇▇
▇▇▇▇▇▇▇, ▇▇ ▇▇▇▇▇
Facsimile: (▇▇▇) ▇▇▇-▇▇▇▇
Attention: ▇▇▇▇▇▇ ▇▇▇▇▇▇
to EMED:
EMED Technologies Corporation
▇▇ ▇▇▇▇▇▇▇▇ ▇▇▇▇▇▇
▇▇▇▇▇▇▇▇▇, ▇▇ ▇▇▇▇▇
Facsimile: (▇▇▇) ▇▇▇-▇▇▇▇
Attention: ▇▇▇▇▇▇ ▇▇▇▇▇▇
Notices sent by certified mail, return receipt requested to the address
specified pursuant to this Section 7.11 shall be effective three business days
after deposit in the U.S. Mail with postage prepaid. Notice delivered by any
other means shall be effective upon receipt.
7.12. No Agency. AWARE and EMED are independent contractors and separate
----------
legal entities and shall in no way be interpreted as partners, joint venturers,
agents, employees or legal representatives of each other for any purposes.
Neither party shall be responsible for or bound
Confidential Treatment
22
by any act of the other party or the other party's agents, employees or any
persons in any capacity in its service.
IN WITNESS WHEREOF, the parties hereto have executed this Agreement as of
the first date set forth above.
EMED TECHNOLOGIES
CORPORATION AWARE, INC.
By: /s/ By: /s/
------------------- -------------------
Name: Name:
Title: Title:
Confidential Treatment
23
Schedule I
Description of Technology
The Web Product accepts medical images, reports, and other information from
various sources, and makes them available for distribution over the web to thin
web clients. Reports are collected and linked with the original studies
(images). The Web Product includes the application defined by EMED, and user
interfaces, features, and web server technology developed by EMED which handles
the image, text, voice and administrative input required for systems operation.
The Web Product further includes HTML generation, web plug-in, compression, and
end-user application software, using core components developed and owned by
AWARE, Inc. In addition, the product consists of user and technical
documentation which have been provided by both parties.
